Grail, AstraZeneca to collaborate on companion diagnostic tests

By LabPulse.com staff writers

June 2, 2022 -- Grail on Thursday announced its strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.

The firms will focus first on developing CDx tests using Grail's methylation platform to identify and recruit patients with high-risk, early-stage cancer for AstraZeneca's clinical studies.

Grail said the collaboration includes plans for numerous studies across multiple indications over the next several years.

Grail has developed a novel approach to detect cancer signals in blood, regardless of whether the patient has clinical symptoms. The company said that it will seek regulatory approval in key markets for its liquid biopsy-based CDx.

Grail collaborates with VA on Galleri study
Grail is collaborating with the U.S. Department of Veterans Affairs (VA) Health Administration on a large-scale observational study assessing the performance...
Intermountain Healthcare to offer Galleri cancer blood test
Utah-based health system Intermountain Healthcare will be offering Grail’s Galleri multicancer early detection blood test as a complement to existing...
Illumina sees revenue increases for Q1 as net income slips
Strong growth across multiple business units helped DNA sequencing developer Illumina report revenue increases for the first quarter of fiscal 2022 (end-April...
Grail to partner with Premier
Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's...
Grail teams with Quest on blood test for early cancer detection
Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood...

Copyright © 2022 LabPulse.com

Last Updated mp 6/2/2022 2:14:40 PM